Answers are grounded in this paper and cite their sources.
Given the potential role of acetylcholinesterase inhibitors (AChEIs) in modulating the cholinergic anti-inflammatory pathway, this study aimed to evaluate their association with short- and long-term mortality in patients with acute kidney injury (AKI), and to explore pharmacological subtype differences and effect heterogeneity. This retrospective cohort study included adult ICU patients with AKI. Patients were categorized by AChEI use and further classified into central and peripheral subtypes. The primary outcome was all-cause mortality at 28, 90, and 365 days. Time-dependent Cox regression anchored at AKI onset was used as the primary analysis, with ICU-admission–anchored time-dependent Cox, 24-h landmark, and overlap-weighting analyses performed as complementary analyses. Subgroup analyses assessed effect heterogeneity. A total of 35,600 patients with AKI were included, of whom 4,512 had a recorded AChEI prescription during follow-up. In the AKI-onset–anchored analysis, overall AChEI exposure was associated with lower 28-, 90-, and 365-day mortality, with fully adjusted HRs of 0.39 (95% CI 0.33–0.46), 0.42 (0.36–0.49), and 0.43 (0.37–0.50), respectively. The inverse association was concentrated among patients with AChEI exposure already present at AKI onset, with corresponding HRs of 0.21 (0.17–0.27), 0.24 (0.19–0.29), and 0.24 (0.20–0.30), whereas first recorded AChEI prescription after AKI onset was not significantly associated with mortality (HRs 1.00 [0.80–1.25], 1.01 [0.82–1.24], and 1.02 [0.84–1.24], respectively). The associations remained similar in complementary ICU-admission–anchored, 24-h landmark, and overlap-weighting analyses. Pharmacological subtype analyses showed significant inverse associations for peripheral AChEIs, which were predominantly represented by neostigmine, whereas no significant associations were observed for central AChEIs. Associations were generally consistent across subgroups, although significant interactions were observed for several clinical characteristics. AChEI exposure was associated with lower short- and long-term mortality in patients with AKI. However, this inverse association was concentrated among patients with exposure already present at AKI onset, whereas initiation after AKI onset was not significantly associated with mortality. Not applicable.
No takes yet. Share an insight, caveat, or question.
Tong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: